Lead by Dahan-Oliel, OT, PH.D., our arthrogryposis multiplex congenita (AMC) research program is a major project aimed at investigating new and innovative clinical treatment options for children living with this condition. AMC occurs in one in 3,000 births. Reduced movement during fetal development, likely due to genetic and/or environmental factors, is thought to be the primary cause of this condition.
Dr. Dahan-Oliel's team works with patients, their families and other researchers, to collect and centralize data on epidemiology, risk factors, treatment effectiveness and whole-genome information collected from children with AMC. This data is helping us to better understand this rare condition to develop treatments that address the long-term needs of people diagnosed with it.